The evidence position
FDA: “The molecular targets through which MOTS-c acts are unknown.” (slide 19) And: “The mechanism(s) by which MOTS-c stimulates AMPK signaling are poorly understood.” (slide 18)
FDA: “FDA did not identify data, such as publicly available clinical studies” (slide 23), and “there is a lack of human data on drug products containing MOTS-c-related BDSs.” (slide 25)
FDA did not identify published in-vivo nonclinical pharmacokinetic studies, nor published nonclinical toxicity studies. (slide 21)
WADA lists MOTS-c under S4.4.1, metabolic modulators, as an AMPK activator — “mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)”. Prohibited at all times.
In July 2026 the US Food and Drug Administration reviewed MOTS-c for the 503A Bulk Drug Substances list and proposed that it not be included. FDA briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026.
The pathways it is reached for
The cell's master energy sensor — when fuel runs low it ignites fat-burning, glucose uptake and mitochondrial renewal while standing down growth.
The folate and B12 cycle that carries single carbon units for methylation and nucleotide synthesis.
The transcription factor that commands the body's own antioxidant and detoxification arsenal.
Mitochondrial function — the cellular power output that fuels every tissue and sets physical stamina.
Insulin sensitivity — how readily cells respond to insulin, the linchpin of metabolic health.
How high your blood sugar runs, and for how long, across the day. Higher is worse: sugar that stays high after meals slowly damages nerves, blood vessels and the eyes, including the lens.
Fasting insulin — a sensitive marker of insulin resistance; chronically high levels signal metabolic strain.
The mitochondrial pathway that dismantles fatty acids into cellular energy — the engine that empties stored and circulating fat.
The quality-control program that finds and clears damaged mitochondria, keeping the cellular power grid clean.
A protein called UCP1 lets a fat cell release energy as heat rather than bank it — real, measurable, and smaller than the internet believes.
Electrons escaping the energy-production chain and reacting with oxygen before they should — a constant leak damages mitochondrial DNA and the machinery producing it.
The mitochondrial permeability transition pore — a channel that opens when a mitochondrion is overloaded with calcium and oxidative stress. Once it opens wide, the membrane potential collapses and the cell dies.
Insulin-receptor and PI3K–akt signaling — the anabolic line that clears glucose, supports the vessel wall and commands cell growth.
What we carry on those pathways
Shares 7 of these pathways: AMPK, Nrf2, Mitochondrial Function, Glycemic Load, Fasting Insulin, Mitochondrial ROS Leak, Mitochondrial Pore (mPTP).
Shares 7 of these pathways: AMPK, Mitochondrial Function, Insulin Sensitivity, Glycemic Load, Fatty-Acid β-Oxidation, Mitochondrial Uncoupling, Insulin-R / PI3K-AKT.
Shares 7 of these pathways: AMPK, Nrf2, Insulin Sensitivity, Glycemic Load, Fasting Insulin, Mitophagy, Insulin-R / PI3K-AKT.
Shares 6 of these pathways: AMPK, Nrf2, Mitochondrial Function, Insulin Sensitivity, Glycemic Load, Fasting Insulin.
Shares 6 of these pathways: AMPK, Insulin Sensitivity, Glycemic Load, Fasting Insulin, Fatty-Acid β-Oxidation, Mitochondrial Uncoupling.
Shares 6 of these pathways: AMPK, Nrf2, Glycemic Load, Fasting Insulin, Fatty-Acid β-Oxidation, Mitochondrial Pore (mPTP).
AMPK → Insulin Sensitivity. “In model systems, sustained decreases in AMPK activity accompany IR, whereas AMPK activation increases insulin sensitivity.” — AMPK, insulin resistance, and the metabolic syndrome. The Journal of Clinical Investigation, 2013, volume 123, issue 7, pages 2764-2772. doi:10.1172/JCI67227
Glycemic Load → Polyol / Sorbitol Pathway. “However, during hyperglycemia the flux of glucose via the polyol pathway increases significantly, leading to excessive formation of sorbitol.” — Physiological and Pathological Roles of Aldose Reductase. Metabolites, 2021, volume 11, issue 10, article 655. doi:10.3390/metabo11100655
Insulin Sensitivity → Male Fertility. “We conclude that diabetes mellitus and insulin resistance affect semen parameters and impair distinct phases of spermatogenesis in male rats.” — Alloxan-induced and Insulin-resistant Diabetes Mellitus affect Semen Parameters and Impair spermatogenesis in Male Rats. African Journal of Reproductive Health, 2006, 10(3), 106-113. African Journal of Reproductive Health 2006;10(3):106-113 (publisher article record read off www.ajrh.info/index.php/ajrh/article/view/724; no DOI or PMID printed on the page, none derived)
Insulin Sensitivity → Women's Hormonal Balance. “A metabolic syndrome of obesity-related and/or intrinsic insulin resistance occurs in about half of PCOS patients, and the compensatory hyperinsulinism has tissue-selective effects, which include aggravation of hyperandrogenism.” — The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocrine Reviews, 2016, 37(5), 467-520. doi:10.1210/er.2015-1104
Insulin Sensitivity → Liver Integrity. “IR worsens NAFLD by increasing the accumulation of free fatty acids (FFAs) in the liver.” — Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. Exploration of Medicine, 2020, 1, 287-306. doi:10.37349/emed.2020.00019
Insulin Sensitivity → Micronutrient Status. “In diabetes, insulin resistance in renal tissue inhibits magnesium reabsorption and contributes to the hypomagnesemia observed in these patients.” — Hypomagnesemia With Metformin Use in Diabetes Mellitus: A Case and Narrative Review. Kidney Medicine, 2025, volume 7, article 101030. doi:10.1016/j.xkme.2025.101030
What a grade means here
Every ingredient row on our formula pages carries one of these grades, fixed by a standard set before the evidence was gathered. The grades below are reproduced from those pages.
Randomized human trials, or a meta-analysis of them, measuring this pathway's own endpoint — either a clinical outcome or a validated biomarker.
Human data, or animal evidence replicated by an independent laboratory. It opens a pathway only alongside an independent corroborating driver.
Mechanistic, cell or animal evidence. No single preclinical driver opens a pathway on its own.
What this page does not claim
Sharing a pathway is not the same as sharing an effect. Nothing here says a botanical formula does what MOTS-c does, and nothing here recommends MOTS-c. The pathways above are named because that is what the published work on MOTS-c points at; the formulas below are listed because our own map records graded, published evidence on those same pathways. Read both columns and judge them yourself — every figure on our side carries its grade and its source.